Seizure Induced by Extended-Release Bupropion Used for Smoking Cessation at Early Term and Therapeutic Dose

被引：0
|
作者：
Ozozen Ayas, Zeynep [1 ]
Aksoy Gundogdu, Asli [2 ]
机构：
[1] Sakarya Univ, Dept Neurol, Training & Res Hosp, Adapazari, Turkey
[2] Namik Kemal Univ, Dept Neurol, Fac Med, Tekirdag, Turkey
来源：
EPILEPSI | 2018年 / 24卷 / 03期
关键词：
Extended-release bupropion; seizure; smoking cessation treatment;
D O I：
10.14744/epilepsi.2018.04796
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Bupropion inhibits reuptakes of dopamine and noradrenaline. Since it is also a nicotine receptor antagonist, it acts as a drug used for smoking cessation. Bupropion is commonly preferred because of no side effects on weight, sexual function, and the lack of sedative effect. Immediate and sustained-release bupropion forms may trigger seizure activity. In the present article, we report a case of a 30-year-old man presenting with generalized tonic clonic seizures induced by extended-release bupropion. We also emphasized that extended-release bupropion, which is commonly used for smoking cessation therapy, may cause seizure at early term and therapeutic dose.
引用
收藏
页码：127 / 129
页数：3
相关论文
共 29 条
  • [21] Do Stimulants Reduce the Risk for Cigarette Smoking in Youth with Attention-Deficit Hyperactivity Disorder? A Prospective, Long-Term, Open-Label Study of Extended-Release Methylphenidate
    Hammerness, Paul
    Joshi, Gagan
    Doyle, Robert
    Georgiopoulos, Anna
    Geller, Daniel
    Spencer, Thomas
    Petty, Carter R.
    Faraone, Stephen V.
    Biederman, Joseph
    JOURNAL OF PEDIATRICS, 2013, 162 (01): : 22 - U287
  • [22] Safety and Efficacy of P2B001 (Low Dose Combination of Extended-release Pramipexole and Rasagiline) in Patients with Early Parkinson's Disease: Subgroup Analyses from a Randomized, Controlled
    Falconer, D.
    Litman, P.
    Friedman, H.
    Oren, S.
    Fitter-Attas, C.
    MOVEMENT DISORDERS, 2023, 38 : S21 - S21
  • [23] Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
    Cheryl H. Waters
    Paul Nausieda
    Lyudmila Dzyak
    Joerg Spiegel
    Monika Rudzinska
    Dee E. Silver
    Elena S. Tsurkalenko
    Sherron Kell
    Ann Hsu
    Sarita Khanna
    Suneel Gupta
    CNS Drugs, 2015, 29 : 341 - 350
  • [24] Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial
    Waters, Cheryl H.
    Nausieda, Paul
    Dzyak, Lyudmila
    Spiegel, Joerg
    Rudzinska, Monika
    Silver, Dee E.
    Tsurkalenko, Elena S.
    Kell, Sherron
    Hsu, Ann
    Khanna, Sarita
    Gupta, Suneel
    CNS DRUGS, 2015, 29 (04) : 341 - 350
  • [25] Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years
    Kisicki, James C.
    Fiske, Kimberly
    Lyne, Andrew
    CLINICAL THERAPEUTICS, 2007, 29 (09) : 1967 - 1979
  • [26] Early treatment with aspirin and extended-release dipyridamole versus low dose aspirin alone for TIA/ischaemic stroke within 24 hour of symptom-onset (EARLY-trial): a randomised, open-label, blinded-endpoint trial
    Dengler, R.
    Diener, H. C.
    Grond, M.
    Haberl, R.
    Leonard, J.
    Machnig, T.
    Schenkel, J.
    Schumacher, H.
    Schwartz, A.
    Weissenborn, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 655 - 655
  • [27] C-reactive Protein and Its Pharmacologic Reduction as Predictor of Outcome in the Early Treatment With Aspirin and Extended-release Dipyridamole versus Low Dose Aspirin Alone for TIA/Ischemic Stroke Within 24 Hour of Symptom-onset (EARLY-Trial)
    Dengler, Reinhard
    Lichtinghagen, Ralf
    Schumacher, Helmut
    Weissenborn, Karin
    Worthmann, Hans
    STROKE, 2010, 41 (04) : E261 - E261
  • [28] Update to interim results of a long-term open-label safety study of ADS-5102 (amantadine HCl) extended-release capsules for treatment of levodopa-induced dyskinesia (LID) (EASE LID 2 Study)
    Hauser, Robert
    Pahwa, Rajesh
    Tanner, Caroline
    Oertel, Wolfgang
    Johnson, Reed
    Felt, Larissa
    Stempien, Mary
    MOVEMENT DISORDERS, 2017, 32 : S42 - S43
  • [29] Double-Blind, Placebo-Controlled Fixed-Dose Trial of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, in Early Parkinson's Disease (APEX-PD Trial)
    Pahwa, Rajesh
    Hauser, Robert
    Jankovic, Joseph
    Nausieda, Paul
    Ellenbogen, Aaron
    Hsu, Ann
    Gupta, Sunell
    NEUROLOGY, 2011, 77 (02) : 199 - 199
123